Your shopping cart is currently empty

VEGFR-2-IN-51 (compound 19) is an orally active dual-target inhibitor of VEGFR-2 (IC50=15.33 μM) and tubulin (IC50=0.76 μM) that exhibits antitumor activity. This compound induces apoptosis in tumor cells by reducing mitochondrial membrane potential and increasing levels of reactive oxygen species (ROS). Additionally, VEGFR-2-IN-51 suppresses angiogenesis through inhibition of the VEGFR-2/PI3K/AKT signaling pathway. Moreover, it demonstrates significant antiproliferative effects on the gastric cancer cell line MGC-803 (IC50=0.005 μM).
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | VEGFR-2-IN-51 (compound 19) is an orally active dual-target inhibitor of VEGFR-2 (IC50=15.33 μM) and tubulin (IC50=0.76 μM) that exhibits antitumor activity. This compound induces apoptosis in tumor cells by reducing mitochondrial membrane potential and increasing levels of reactive oxygen species (ROS). Additionally, VEGFR-2-IN-51 suppresses angiogenesis through inhibition of the VEGFR-2/PI3K/AKT signaling pathway. Moreover, it demonstrates significant antiproliferative effects on the gastric cancer cell line MGC-803 (IC50=0.005 μM). |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.